RXST vs. STAA, BHC, WRBY, EYE, EDAP, CLPT, STIM, APYX, BLCO, and VERA
Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include STAAR Surgical (STAA), Bausch Health Companies (BHC), Warby Parker (WRBY), National Vision (EYE), Edap Tms (EDAP), ClearPoint Neuro (CLPT), Neuronetics (STIM), Apyx Medical (APYX), Bausch + Lomb (BLCO), and Vera Therapeutics (VERA). These companies are all part of the "medical" sector.
STAAR Surgical (NASDAQ:STAA) and RxSight (NASDAQ:RXST) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
In the previous week, RxSight had 1 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for RxSight and 6 mentions for STAAR Surgical. STAAR Surgical's average media sentiment score of 0.82 beat RxSight's score of 0.47 indicating that RxSight is being referred to more favorably in the news media.
96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.0% of STAAR Surgical shares are owned by company insiders. Comparatively, 21.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
STAAR Surgical has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
STAAR Surgical has a net margin of 4.69% compared to STAAR Surgical's net margin of -44.01%. RxSight's return on equity of 6.83% beat STAAR Surgical's return on equity.
STAAR Surgical has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
STAAR Surgical currently has a consensus price target of $47.13, suggesting a potential upside of 10.57%. RxSight has a consensus price target of $60.63, suggesting a potential downside of 2.63%. Given RxSight's higher probable upside, equities research analysts plainly believe STAAR Surgical is more favorable than RxSight.
STAAR Surgical received 249 more outperform votes than RxSight when rated by MarketBeat users. However, 66.67% of users gave RxSight an outperform vote while only 56.10% of users gave STAAR Surgical an outperform vote.
Summary
STAAR Surgical beats RxSight on 10 of the 18 factors compared between the two stocks.
Get RxSight News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
